[Author Disclosure: This content reflects the views of the author and is provided for informational purposes only. It does not constitute investment advice and is not a recommendation or endorsement by BioTech Funding Portal. Any investment decision should be based solely on the issuer’s official offering materials.]
A pharma company will almost always choose a blockbuster over a small patient population. That's not cynicism — it's how the economics of a multibillion-dollar portfolio actually work.
It's also exactly why rare diseases like Fabry, Pompe, and Gaucher stay underserved relative to their severity, and why community funding models — ours included — exist at all. A therapy addressing a few thousand people worldwide will never compete internally with a blockbuster franchise, even when the underlying science is just as real.
That's the gap Glafabra is built to sit in.
If a company you cared about was too small for big pharma's math but big enough to matter to you — would you want the chance to fund it directly?
Follow the whole series: https://bit.ly/Glafabra-TTW
@Brian Christie @Neva West @Chris Hopkins @Tetsu Yung
Testing the Waters disclosure: We are considering a capital raise and are "Testing the Waters" under Regulation Crowdfunding. No money or other consideration is being solicited, and any that is sent in response will not be accepted. We cannot accept any offer to buy securities, and no part of the purchase price can be received until an offering statement is filed and only through the BioTech Funding Portal platform. Any indication of interest is non-binding and involves no obligation or commitment of any kind.
Register for FREE to comment or continue reading this article. Already registered? Login here.
0